DataMeds AI Stock Rises Following Website Launch, Acquisition

By EC Assets · Published 21 September 2026

DataMeds AI stock experienced a surge following a new website launch. This development comes after the company completed an acquisition. The stock is listed under the ticker MEDS on NASDAQ. DataMeds AI Inc. recently completed a $1.5 million acquisition of Helomics. This transaction expands DataMeds into cancer diagnostics. The acquisition adds a certified oncology laboratory, contract research services, and $1.5 million in cash to DataMeds. Axe Compute concurrently exited its remaining cancer testing business. In a separate development, DataMeds AI expanded its license with DataVault AI. This license focuses on data-driven outcome healthcare-focused blockchain and data monetization. Healthcare data constitutes over 30% of global data assets and grows by 36% annually. DVLT and MEDS have patented technology platforms designed to value, score, and monetize healthcare data. This article is intended for informational purposes only. It does not constitute investment advice.